bpc 157 peptide clinical evidence and safety BPC-157 the Difference Between an Gap and a Cover-Up: What the entire human evidence base actually looks like, and the questions to ask next. — WellFounded BPC-157 – Research Peptide |

Are Oral Peptides Effective

The underconsumed and underappreciated essential nutrient

*Come in for a free consultation, all treatments can be converted to tailor your needs

Active cancer or history of malignancy Pregnancy or breastfeeding Known peptide allergies Athletes subject to anti-doping testing (WADA prohibited) Raynauds disease or phenomenon Cold urticaria (hives from cold) Uncontrolled hypertension Peripheral vascular disease Open wounds (for local application) Pregnancy Cardiovascular conditions Diabetes (especially with neuropathy) Current infections Immunosuppression Blood clotting disorders Quality control issues represent perhaps the greatest practical risk with BPC-157

[DOI] [PubMed] [Google Scholar] 395.Yin L, Cheng J, Deming TJ, Vicent MJ

The theoretical concern about angiogenesis-driven tumor promotion persists despite absence of evidence specifically because the question has not been adequately studied in humans over meaningful timeframes